Serologies in Crohn's Disease: Can We Change the Gray Zone to Black and White?

Gastroenterology

Volumn 131, Issue 2, 2006, Pages 664-667

  Abreu, María T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIUM ANTIBODY; BIOLOGICAL MARKER; CHITOBIOSIDE CARBOHYDRATE ANTIBODY; FLAGELLIN; LAMINARIBIOSIDE CARBOHYDRATE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; OUTER MEMBRANE PROTEIN C; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; CROHN DISEASE; DISEASE CLASSIFICATION; EDITORIAL; ENTERITIS; ESCHERICHIA COLI; GASTROINTESTINAL SURGERY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; IMMUNOREACTIVITY; INNATE IMMUNITY; NEUTROPHIL; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS FLUORESCENS; QUALITATIVE ANALYSIS; SACCHAROMYCES CEREVISIAE; SENSITIVITY ANALYSIS; SEROLOGY; TREATMENT INDICATION; ULCERATIVE COLITIS;

EID: 33746544387     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.06.040     Document Type: Editorial

References (10)

1. Hommes D., Baert F., Van Assche G., Caenepeel F., Vergauwe P., Tuynman H., De Vos M., Van Deventer S., Stitt L., Rutgeerts P., Feagan B., and D'Haens G. Management of recent onset Crohn's disease. a controlled, randomized trial comparing step-up and top-down therapy. Gastroenterology 129 (2005) 371
2. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., and Hanauer S.B. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126 (2004) 402-413
3. Sans M., Artieda M., Diego T., Cara C., Rodrigo L., Barreiro M., Arroyo M.T., Aceituno M., Alvarez-Lobos M., Yague J., Arostegui J.I., Quinto L., Simon L., Pique J.M., Martinez A., and Panes J. IBDChip. A new strategy to predict clinical course and development of complications in patients with inflammatory bowel disease. Gastroenterology 130 (2006) A346
4. Seibold F., Brandwein S., Simpson S., Terhorst C., and Elson C.O. pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 18 (1998) 153-160
5. Landers C.J., Cohavy O., Misra R., Yang H., Lin Y.C., Braun J., and Targan S.R. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123 (2002) 689-699
6. Lodes M.J., Cong Y., Elson C.O., Mohamath R., Landers C.J., Targan S.R., Fort M., and Hershberg R.M. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 113 (2004) 1296-1306
7. Targan S.R., Landers C.J., Yang H., Lodes M.J., Cong Y., Papadakis K.A., Vasiliauskas E., Elson C.O., and Hershberg R.M. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology 128 (2005) 2020-2028
8. Dotan I., Fishman S., Dgani Y., Schwartz M., Karban A., Lerner A., Weishauss O., Spector L., Shtevi A., Altstock R.T., Dotan N., and Halpern Z. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 131 (2006) 366-378
9. Schwarz M., Spector L., Gargir A., Shtevi A., Gortler M., Altstock R.T., Dukler A.A., and Dotan N. A new kind of carbohydrate array, its use for profiling antiglycan antibodies, and the discovery of a novel human cellulose-binding antibody. Glycobiology 13 (2003) 749-754
10. Mow W.S., Vasiliauskas E.A., Lin Y.-C., Fleshner P.R., Papadakis K.A., Taylor K.D., Landers C.J., Abreu M.T., Rotter J.I., Yang H., and Targan S.R. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 126 (2004) 414-424